Ziprasidone, a new atypical antipsychotic drug

Pharmacotherapy

Volumn 21, Issue 6, 2001, Pages 717-730

  Carnahan, R M ^a   Lund, B C ^a   Perry, P J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CIMETIDINE; CLOZAPINE; CYTOCHROME P450 INHIBITOR; DEXTROMETHORPHAN; DEXTRORPHAN; ENZYME INDUCING AGENT; ETHINYLESTRADIOL; HALOPERIDOL; KETOCONAZOLE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGITATION; AKATHISIA; ANTICHOLINERGIC EFFECT; BODY WEIGHT DISORDER; CARDIOTOXICITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERPROLACTINEMIA; LABORATORY TEST; LIPID BLOOD LEVEL; MAINTENANCE THERAPY; MANIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RASH; REVIEW; SCHIZOIDISM; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; VERTIGO;

EID: 0034987259     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.7.717.34575     Document Type: Review

References (46)

1. Schizophrenia
2. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
3. Defining the phenotype of schizophrenia: Cognitive dysmetria and its neural mechanisms
4. Assessing the effects of atypical antipsychotics on negative symptoms
5. Negative symptoms: A path-analytic approach to a double-blind, placebo- and haloperidol -controlled clinical trial with olanzapine
6. Drug treatment strategies and treatment-resistant schizophrenia
7. Compliance with antipsychotic drug treatment: Influence of side-effects
8. Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs
9. 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents
10. Antipsychotic drug mechanism and neurotransmitter systems in schizophrenia
11. Serotonin-dopamine interaction and its relevance to schizophrenia
12. Preclinical pharmacology of neuroleptics: Focus on new generation compounds
13. Ziprasidone (CP-88 059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
14. The novel antipsychotic ziprasidone has a unique human receptor binding profile compared with other agents
15. Single and multiple dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers
16. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions
17. Transection of the oesophagus for bleeding varices
18. The pharmacokinetics of ziprasidone in patients with normal and impaired hepatic function
19. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function
20. Single and multiple dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers
21. The effects of ketoconazole on ziprasidone pharmacokinetics: A placebo-controlled crossover study in healthy volunteers
22. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid
23. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers
24. Ziprasidone and the pharmacokinetics of a combined oral contraceptive
25. Ziprasidone and the activity of CYP 2D6 in healthy extensive metabolizers
26. The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium
27. Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study
28. A 3-week, double blind, randomized trial of ziprasidone in the acute treatment of mania
29. A randomized, double-blind comparison of rapid-acting, intramuscular ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation
30. Rapid-acting, intramuscular ziprasidone 10 mg and 20 mg in patients with psychosis and acute agitation: Results of two double-blind, randomized, fixed-dose studies
31. An overview of the efficacy and safety of rapid-acting intramuscular ziprasidone
32. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
33. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
34. Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia
35. A 28-week comparison of flexible-dose ziprasidone with haloperidol in outpatients with stable schizophrenia
36. Benefits of ziprasidone in stable outpatients with schizophrenia switched from conventional antipsychotics, olanzapine or risperidone
37. Improvement in indices of health status in outpatients with schizophrenia following a switch to ziprasidone from conventional antipsychotics, olanzapine or risperidone
38. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months
39. Side effects of new antipsychotic agents
40. Antipsychotic -induced weight gain: A comprehensive research synthesis
41. Prolactin and antipsychotic medications: Mechanism of action
42. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations